{"id":"W2532238474","doi":"10.1111/jdv.14015","title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":198,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Cilag; Regeneron Pharmaceuticals; UCB Pharma; Medac; LEO Pharma; Eli Lilly and Company; Galderma; Biogen; Celgene; GlaxoSmithKline; Amgen; Pfizer","keywords":"Medicine; Apremilast; Placebo; Etanercept; Psoriasis; Randomized controlled trial; Dermatology; Internal medicine; Physical therapy; Psoriatic arthritis; Alternative medicine; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004582761,0.001451593,0.003114905,0.0004073581,0.0005598462,0.001203156,0.0008268948,0.001891649,0.006143229],"category_scores_gemma":[0.002634875,0.0008951644,0.002020682,0.0003644188,0.001020484,0.001137869,0.0004355731,0.003514849,0.0009046532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006078963,"about_ca_system_score_gemma":0.001054797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004029889,"about_ca_topic_score_gemma":0.0008448545,"domain_scores_codex":[0.9986045,0.0008122487,0.0001242276,0.000195384,0.0001400348,0.0001236029],"domain_scores_gemma":[0.9981247,0.0005656033,0.0005143177,0.000139449,0.0001172225,0.0005387644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9671013,0.01079684,0.0007180265,0.0005105493,0.0006848271,0.00002811602,0.00005546957,0.00015138,0.004057091,0.00004262111,0.0005561208,0.01529768],"study_design_scores_gemma":[0.9339675,0.06288736,0.002157995,0.00002388466,0.0002365161,0.00003196075,0.0000105583,0.000133292,0.0002996058,0.00003640222,0.0002068089,0.000008156324],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852642,0.007215041,0.000706238,0.0007045808,0.000384789,0.003171395,0.0008313379,0.0001223928,0.001600113],"genre_scores_gemma":[0.9859773,0.003328184,0.001925278,0.001264993,0.0006201373,0.003901758,0.0009624662,0.0000287472,0.001991127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006143229,"threshold_uncertainty_score":0.02423626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01107462923802612,"score_gpt":0.2306057609492769,"score_spread":0.2195311317112508,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}